Companies: 10,795·Total market cap: $144.5T
Virax Biolabs Group Limited

Virax Biolabs Group Limited

VRAXNASDAQHealthcare● Active
$0.21
$-0.00(-1.74%)
Market Cap$906600
P/E Ratio
52W High$1.14
52W Low$0.1
Overview

Virax Biolabs Group Limited (VRAX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · VRAX · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-3.85vrax eps ttm · vrax earnings per shareEarnings history
PE Ratio (TTM)vrax pe ratio ttm · vrax price to earningsPE Ratio deep dive
Revenue (TTM)87858.00vrax revenue ttm · vrax annual revenueFull revenue history
Dividend YieldNo Dividenddoes vrax pay dividends · vrax dividend yieldDividend history
Shares Outstanding3.1Mvrax shares outstanding · vrax floatShares outstanding history
Next EarningsDec 2, 2026Est.vrax earnings date · vrax next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$6331.00▼ 95.95% YoY
202320242025
virax biolabs group limited revenue · vrax revenue 2025
FY 2025Net Income-$6.1M▲ +9.98% YoY
202320242025
virax biolabs group limited net income · vrax profit 2025
FY 2025EPS$-1.96▲ +41.67% YoY
202320242025
vrax eps · virax biolabs group limited earnings per share 2025
TTM:Revenue: $87858.00Net Income: -$12.2MEPS: $-3.85View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy1 analystsis vrax a buy · vrax analyst rating
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$1.00Low
$0.21Current
$1.00Avg Target378.93% upside
$1.00High
vrax price target · vrax 12 month forecast

Total: 1 · Buy rate: 100.0%

The VRAX analyst consensus is Buy, based on ratings from 1 Wall Street analysts over the past 3 months. The average 12-month price target is $1.00, representing +378.93% upside from the current price of $0.21.

Stock Performance

Full History
1D-1.74%
1W+4.92%
1M+22.11%
3M+4.40%
YTD-39.62%
1Y-79.33%
5Y-99.89%

About Virax Biolabs Group Limited

CEOJames Foster
IPO DateJul 21, 2022
Employees17
CountryGB

Virax Biolabs Group Limited is a biotechnology firm that specializes in the sale, distribution, and promotion of diagnostic testing kits, medical technology, and personal protective equipment (PPE). I…

what is virax biolabs group limited · vrax stock overview · virax biolabs group limited company profile · who is virax biolabs group limited ceo · vrax NASDAQ · virax biolabs group limited headquarters · virax biolabs group limited business segments

About Stock Overview & Key Data

Virax Biolabs Group Limited (VRAX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 21, 2022. As of the latest trading session, VRAX stock price is $0.21, with a market capitalization of $906,600. The stock has returned -79.33% over the past 12 months and -39.62% year-to-date.

According to 1 Wall Street analysts, the consensus rating for Virax Biolabs Group Limited stock is Buy, with an average 12-month price target of $1.00. In fiscal year 2025, Virax Biolabs Group Limited reported revenue of $6331.00 and net income of -$6.1M. For detailed data — including Virax Biolabs Group Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Virax Biolabs Group Limited (VRAX) stock price is $0.21. The stock is traded on NASDAQ under the ticker symbol VRAX. The 52-week range is $0.10 – $1.14.

VRAX stock priceVRAX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice